CRISPR Technology Market Forecast Report 2024 - Market Forecast to Reach USD 7.5 Billion by 2029 with a 14.4% CAGR
October 31, 2024 12:36 ET
|
Research and Markets
Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology Market" report has been added to ResearchAndMarkets.com's offering.The CRISPR Technology Market was valued at USD 2024 in 2029, and...
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
October 31, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November...
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
October 24, 2024 08:01 ET
|
Intellia Therapeutics, Inc.
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16,...
Ancilia Biosciences Selected to Receive $3 Million Award from ARPA-H’s Sprint for Women’s Health
October 23, 2024 13:05 ET
|
Ancilia Biosciences
Ancilia has been awarded $3M from the prestigious ARPA-H Sprint for Women’s Health to develop a novel therapy for bacterial vaginosis through IND filing.
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs
October 21, 2024 10:54 ET
|
Research and Markets
Dublin, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The "CRISPR-based Gene Editing Market Size, Share and Trends Analysis Report by Product & Service (CRISPR Kits & Reagents), Application (Biomedical,...
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
October 07, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to...
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
October 01, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR...
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
September 12, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
September 11, 2024 08:00 ET
|
Halberd Corp.
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
September 03, 2024 08:00 ET
|
Caribou Biosciences, Inc.
-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track...